Rocylteine 600 Mg/200 mg Tablets

ROCYLTEINE is used as a mucolytic, of non-infective secretions in cystic fibrosis and in respiratory conditions.

Posology: Children from 2 to 5 years of age: ROCYLTEINE 200 mg: u00bd (half) an effervescent tablet 2 to 3 times daily (equivalent to 200 to 300 mg acetylcysteine/day). Children from 6 to 14 years of age: ROCYLTEINE 200 mg: 1 effervescent tablet twice daily (equivalent to 400 mg acetylcysteine/day). Adults and adolescents from 14 years of age: ROCYLTEINE 200 mg: 1 effervescent tablet 2 to 3 times daily (equivalent to 400 to 600 mg acetylcysteine/day). ROCYLTEINE 600 mg: u00bd effervescent tablet twice daily or 1 effervescent tablet once daily (equivalent to 600 mg acetylcysteine per day). Do not use continuously for more than 14 days without consulting a doctor.

Method of administration: Oral use. ROCYLTEINE should be dissolved in a glass of water before use.

• Hypersensitivity to acetylcysteine or any of the other ingredients of ROCYLTEINE effervescent tablets (see section 6.1).
• Safety in pregnancy has not been established. ROCYLTEINE effervescent tablets should not be used during pregnancy (see section 4.6).
• Active peptic ulceration.
• ROCYLTEINE is contraindicated in children below 2 years of age.

The occurrence of severe skin reactions such as Stevens-Johnson syndrome and Lyell's syndrome has very rarely been reported in temporal connection with the use of acetylcysteine, as contained in ROCYLTEINE. If cutaneous and mucous membrane changes appear, medical advice should be sought immediately and the use of ROCYLTEINE be stopped (see also section 4.8). Patients with bronchial asthma should be closely monitored during therapy. If bronchospasm occurs, ROCYLTEINE should be stopped immediately and appropriate treatment must be instituted. Caution is advised with the use of ROCYLTEINE in patients with a history of ulcer, especially if, in addition, other medicines are taken that are irritating to the mucous membranes of the Gastrointestinal tract. Medicine-induced nausea and vomiting may occur and may increase the risk of gastrointestinal haemorrhage in patients predisposed to the condition. Mucolytics, including ROCYLTEINE may disrupt the gastric mucosal barrier. Caution should be exercised in patients with histamine intolerance. Long-term therapy of these patients should be avoided as acetylcysteine affects histamine metabolism and may lead to symptoms of intolerance (e.g. headache, runny nose, itching). Use of ROCYLTEINE, especially at the beginning of treatment, can cause a liquefaction and thus lead to an increase in the volume of the bronchial secretion. If the patient is unable to cough this up sufficiently, appropriate measures should be taken (e.g. postural drainage and suction). Children under 2 years of age ROCYLTEINE must not be used in children under 2 years of age (see section 4.3). ROCYLTEINE contains sodium hydrogen bicarbonate 85 mg in ROCYLTEINE 200 mg and 240 mg in ROCYLTEINE 600 mg, corresponding to 4,25 % and 12 % of the WHO recommended maximum daily sodium intake with food of 2 g. This should be taken into account in people taking controlled sodium (low-sodium / low-sodium) diet. ROCYLTEINE contains aspartame. Aspartame is a source of phenylalanine and can be harmful to patients with phenylketonuria. ROCYLTEINE contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take ROCYLTEINE.

Interaction studies have only been conducted in adults. With the combined use of mucolytic medicines such as acetylcysteine with antitussives (cough suppressants), a dangerous accumulation of secretion can arise due to the restricted cough reflex. An especially careful diagnosis is required for this combination treatment. The use of activated charcoal can reduce the effects of acetylcysteine. Reports of inactivation of antibiotics (tetracycline with exception of doxycycline, aminoglycosides, penicillins) by acetylcysteine has so far only concerned in-vitro experiments in which the relevant substances were mixed directly. Oral antibiotics should be administered separately from ROCYLTEINE and at least two hours apart. Acetylcysteine / nitroglycerin Concomitant administration of ROCYLTEINE can possibly increase the vasodilatory effect of glycerol trinitrate (nitroglycerin). If co-treatment with nitroglycerin and ROCYLTEINE is considered necessary, the patient should be monitored for the development of hypotension that may be severe and be advised that headache may occur. Simultaneous intake of acetylcysteine and carbamazepine can result in sub-therapeutic carbamazepine concentrations.

Changes in the determination of laboratory parameters: Acetylcysteine can influence the colorimetric determination of salicylates. During urine tests, acetylcysteine can affect the results of the determination of ketone bodies. Dissolving ROCYLTEINE with other medicines is not recommended.

Pregnancy: Safety and efficacy of acetylcysteine in pregnancy and lactation have not been established (see section 4.3). For acetylcysteine there are insufficient clinical data on exposed pregnant women. Animal studies of reproductive toxicology do not indicate direct or indirect harmful effects. ROCYLTEINE should not be used during pregnancy.

Breastfeeding: No information is available on the excretion of acetylcysteine or its metabolites into breast milk. A risk to the breast-fed child cannot be excluded. The use of ROCYLTEINE during breastfeeding is not recommended.

Fertility: There are no data on the influence of acetylcysteine on human fertility. In animal studies, no harmful effects on fertility were observed for therapy-relevant doses of acetylcysteine.

ROCYLTEINE has no known influence on the ability to drive or use machinery.

The most common side effects associated with oral use of ROCYLTEINE affect the gastrointestinal tract. Hypersensitivity reactions, including anaphylactic shock, anaphylactic / anaphylactoid reactions, bronchospasm, angioedema, rash and itching were reported less frequently.

Tabulated list of adverse reactions:

System Organ Class Frequency Category Immune system disorders: Hypersensitivity reactions, angioedema Anaphylactic shock, Anaphylactic / anaphylactoid reactions Less frequent Nervous system disorders: Headache, convulsions, syncope Less frequent Ear and labyrinth disorders: Tinnitus Less frequent Eye disorders: Blurred vision Less frequent Cardiac disorders: Tachycardia Less frequent Vascular disorders: Haemorrhage Hypertension Less frequent Respiratory, thoracic and mediastinal disorders: Bronchial spasm, - predominantly in patients with hyperactive reactive bronchial system in association with bronchial asthma. Dyspnoea Less frequent Gastrointestinal disorders: Vomiting Less frequent Diarrhoea Stomach pain Stomatitis Nausea Dyspepsia Frequency unknown Skin and subcutaneous tissues disorders: Stevens - Johnson syndrome (see section 4.4), toxic epidermal necrolysis, exanthema, pruritus, flushing. Urticaria Rash Itching (pruritis) Less frequent General disorders and administration site conditions: Fever Hypotension Less frequent Facial oedema Frequency unknown Various studies have confirmed a decrease in platelet aggregation during the use of acetylcysteine. The clinical significance of this is so far unclear.

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via The u20186.04 Adverse Reactions Reporting Formu2019. Found under SAHPRAu2019s publications: https://www/sahpra.org.za/Publications/Index/8.

Overdoses may lead to gastrointestinal symptoms, such as nausea, vomiting and diarrhoea. Infants are at risk of hypersecretion. Treatment of overdose is supportive and symptomatic.